60 Degrees Pharmaceuticals, Inc.
SXTP
$1.75
-$0.11-5.91%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 128.90% | 12.09% | 2.63% | -50.39% | -74.94% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 128.90% | 12.09% | 2.63% | -50.39% | -74.94% |
| Cost of Revenue | 279.89% | 289.22% | 36.93% | 21.76% | 17.24% |
| Gross Profit | -308.00% | -450.20% | -56.87% | -104.34% | -273.44% |
| SG&A Expenses | 78.62% | 165.61% | 138.55% | 225.37% | 127.55% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 141.04% | 209.27% | 103.50% | 139.11% | 76.14% |
| Operating Income | -141.65% | -238.70% | -118.16% | -194.49% | -154.92% |
| Income Before Tax | -131.35% | 82.14% | 89.98% | 38.26% | 41.46% |
| Income Tax Expenses | -- | 250.00% | 0.00% | -33.33% | -100.00% |
| Earnings from Continuing Operations | -131.37% | 82.13% | 89.98% | 38.27% | 41.47% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 338.64% | 1,969.57% | 3,418.75% | 1,333.33% | 60.00% |
| Net Income | -130.84% | 82.65% | 90.66% | 39.08% | 41.57% |
| EBIT | -141.65% | -238.70% | -118.16% | -194.49% | -154.92% |
| EBITDA | -143.54% | -242.76% | -119.75% | -197.14% | -156.95% |
| EPS Basic | 70.57% | 102.82% | 71.88% | 5.49% | -62.49% |
| Normalized Basic EPS | 75.60% | 71.53% | 51.98% | -9.27% | -90.97% |
| EPS Diluted | 70.57% | 102.82% | 71.88% | 5.49% | -62.49% |
| Normalized Diluted EPS | 75.60% | 71.53% | 51.98% | -9.27% | -90.97% |
| Average Basic Shares Outstanding | 361.35% | 254.18% | 151.30% | 122.56% | -98.90% |
| Average Diluted Shares Outstanding | 361.35% | 254.18% | 151.30% | -98.61% | -99.45% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
